Inspire Medical Systems, Inc.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
INSP$64.33+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited)
(in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net (loss) earnings | $(11,294) | $2,992 |
| Adjustments to reconcile net (loss) earnings to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 5,110 | 3,044 |
| Accretion of investment discount | (290) | (1,209) |
| Stock-based compensation expense | 30,689 | 31,056 |
| Deferred income tax expense | 1,009 | — |
| Provision for estimated credit losses | 186 | 311 |
| Other non-cash expenses | 548 | 512 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 14,285 | 263 |
| Inventories | (20,942) | (19,609) |
| Prepaid expenses and other current assets | (1,262) | 1,769 |
| Accounts payable | 7,132 | (9,517) |
| Accrued expenses and other liabilities | (12,322) | (16,315) |
| Net cash provided by (used in) operating activities | 12,849 | (6,703) |
| Investing activities | ||
| Capital expenditures | (9,726) | (8,407) |
| Purchases of investments | (57,312) | (17,319) |
| Proceeds from sales or maturities of investments | 55,789 | 24,173 |
| Net cash (used in) investing activities | (11,249) | (1,553) |
| Financing activities | ||
| Proceeds from the exercise of stock options | 109 | 6,441 |
| Share repurchase of common stock | — | (75,009) |
| Payment of taxes on net share settlement of equity awards | (7,591) | (19,192) |
| Net cash (used in) financing activities | (7,482) | (87,760) |
| Effect of exchange rate on cash | 1 | (252) |
| (Decrease) in cash and cash equivalents | (5,881) | (96,268) |
| Cash and cash equivalents at beginning of period | 104,813 | 150,150 |
| Cash and cash equivalents at end of period | $98,932 | $53,882 |
| Supplemental cash flow information | ||
| Cash paid for interest | $16 | $— |
| Capital expenditures included in accounts payable and accrued expenses | 2,986 | 3,272 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.